Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04672252 · ClinicalTrials.gov registry record · Phase 2

The Use of Cannabidiol (CBD) in Pain Reduction and Opioid Use After Shoulder Arthroscopy

A Phase 2 study, sponsored by NYU Langone Health.

Completed
Registry status
Phase 2
Development phase
100
Enrollment target

NCT04672252: Completed Phase 2 study, sponsored by NYU Langone Health.

NCT04672252 is a Phase 2 study that has completed, run by NYU Langone Health. The registered enrollment target is 100 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04672252, a Phase 2 study, has completed, sponsored by NYU Langone Health.

COMPLETED
Registry status
Phase 2
Development phase
100 participants
Enrollment target

Study Summary

This study is designed to evaluate the effects of administering CBD to control post-operative pain in patients undergoing shoulder arthroscopy. Secondly, the purpose will be to evaluate the effectiveness of CBD in comparison with opioid therapy for post-operative pain.

Primary Outcome

Pain severity scores at rest will be assessed by use of a visual analog scale (VAS; 0 = no pain, 10 = worst pain imaginable).

Interventions

  • DRUG CBD Oral Disintegrating Tablet (ODT)
  • OTHER Placebo ODT

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2020-12-01
Est. Completion 2022-12-16
Phase Phase 2
NYU Langone Health

1,164 total trials

What the finished NCT04672252 record still lists

NCT04672252 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% lower).

The record links to 0 conditions, and to 2 interventions - of which CBD Oral Disintegrating Tablet (ODT) is the first listed.

NCT04672252 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04672252 about?

NCT04672252 is a clinical study titled "The Use of Cannabidiol (CBD) in Pain Reduction and Opioid Use After Shoulder Arthroscopy". This study is designed to evaluate the effects of administering CBD to control post-operative pain in patients undergoing shoulder arthroscopy. Secondly, the purpose will be to evaluate the effectiveness of CBD in comparison with opioid therapy for post-operative pain.

What is the current status of trial NCT04672252?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2020-12-01. Estimated completion is 2022-12-16.

What interventions are being tested in trial NCT04672252?

The interventions under investigation include: CBD Oral Disintegrating Tablet (ODT) (DRUG), Placebo ODT (OTHER).

Who is sponsoring clinical trial NCT04672252?

This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04672252's enrollment target sits among peer trials

100 672nd of 2000 higher than 1,263 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04672252, the US trial registry maintained by the National Library of Medicine. NCT04672252 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.